Brain aromatase modulates cardiac functions in embryonic zebrafish

Zulvikar Syambani Ulhaq

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University of Malang, Batu, Indonesia

ABSTRACT

Oestradiol (E2) is known as a female reproductive hormone with pleiotropic effects on the cardiovascular system. Local E2 biosynthesis such as in the brain and myocardial cells have important physiological and pathophysiological roles. E2 production is catalysed by aromatase (Aro) enzyme. In teleost, two Aro isoforms are distinctly expressed in the ovary and brain. In this study, the role of brain Aro (AroB) in modulating cardiovascular system is investigated. AroB MO-mediated knockdown decreased ventricular functions. Moreover, embryos injected with AroB MO displays a sign in developing heart failure. All the effects caused by AroB MO were partially reversed by exposure to E2. Taken together, this study demonstrates the role of AroB in modulating normal cardiovascular function in zebrafish embryos.

1. Introduction

E2 is synthesized from testosterone by the action of Aro enzyme [1]. Interestingly, zebrafish have two Aro isoforms, ovarian Aro (AroA) and brain Aro (AroB), encoded by cyp19a1a and cyp19a1b, respectively [2]. Previously, it has been reported that knocking down of AroB decreased the heart rate (HR) in zebrafish [3], indicating that oestradiol produced in the brain regulates the heart and circulatory physiology during development. In addition, zebrafish exposed to Aro inhibitor (AI) affect embryonic heart and function [4]. Indeed, Aro is expressed in the heart tissues in mice [5]. Though there is a variation of Aro isoforms expressed in teleost fish heart [3], together these reports suggest a prominent role of E2 in the cardiovascular system.

Oestrogen signalling pathways are mainly through the binding of E2 to the oestrogen receptor (ER) that plays a critical role during sex differentiation, brain development and cardiovascular physiology [3,6]. ERα has been reported predominantly expressed in rat ventricular myocytes and zebrafish heart [7,8]. Furthermore, treatment of E2 and ERα attenuated isoproterenol-induced cardiac hypertrophy in H9c2 cells [9], indicating beneficial action of E2-induced cardioprotection. Moreover, overexpression of Aro improved functional recovery post-ischaemia in mice [10]. Although gonadal tissue is the main site for E2 synthesis, locally E2 production in extragonadal tissues such as heart and brain likely has a specific role on these organs. Therefore, this study helps to reveal the possible functions of E2 produced by AroB in modulating normal heart development and function in embryonic zebrafish.

2. Materials and methods

2.1. Fish maintenance and embryo culture

Adult zebrafish (Danio rerio) purchased from a local pet store were raised in a 60-litre tank at 26–30°C under the 14 h dark/10 h light cycle. Fertilized eggs were rinsed in embryo medium (EM) (0.004% CaCl2, 0.163% MgSO4, 0.1% NaCl and 0.003% KCl) and cultured in a six-well plate (30 eggs/8 mL EM/well) at 28 ± 0.5°C. All experimental procedures and maintenance of fish were conducted in accordance with the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health [11].

2.2. Exposure experiment

17β-oestradiol (E2, Sigma) was dissolved in dimethyl sulfoxide (DMSO) and diluted in EM at the concentrations indicated in the experiments. The final concentration of DMSO was 0.1%, which was also used for vehicle control. Exposure started at 2 hpf and the media were changed daily.

2.3. Morpholino-mediated knockdown of AroB

Morpholino antisense oligonucleotides (MO) were purchased from Gene Tools (USA). The sequence of AroB MO designed to block translation of cyp19a1b mRNA and its inverted sequence for injection control (InvB MO) were used in the previous study [3]. The efficacy of AroB MO-mediated knockdown was previously evaluated [3].
2.4. Measurement of cardiac functions

Embryos at 48 hpf were mounted in 3% Methyl Cellulose and the videos were recorded under a light microscope (Olympus CX21) for 1 min. Cardiac functions then were measured as previously described [12–14]. Eight to ten embryos per group were examined, and the experiments were repeated three times with eggs collected from different spawns.

2.5. Statistical analysis

Data were presented as mean ± SEM. Statistical differences between groups were evaluated by one-way ANOVA followed by the least significant difference (LSD) post hoc test using StatPlus. Significant differences were accepted when *p < 0.05.*

3. Results

To determine whether AroB plays an important role in cardiac functions, MO experiment was performed. AroB MO used in this experiment is characterized from a previous study [3]. There is no off-target effect caused by AroB MO, and the injection of 5 ng/nL AroB MO able to inhibit the translation of AroB [3], indicating the specificity of AroB MO. Heart ventricle size was evaluated by measuring the width, length and cross-sectional area during diastolic and systolic phase (Figure 1(a)). When AroB MO was injected, there were no significant changes in the width of ventricle during diastolic or systolic phase (Figure 1(b)-(a)). Length of the ventricle was significantly decreased in 2.5 ng/nL and 5 ng/nL groups, while cross-sectional area of the ventricle was significantly decreased only in 5 ng/nL group compared to uninjected control during diastolic phase, but not systolic phase (Figure 1(b),(c)). Moreover, embryos injected with 5 ng/nL AroB MO showed a significant decreased on end-diastolic volume (EDV), stroke volume (SV), fractional shortening (FS) and cardiac output (CO) compared to uninjected control, but not end-systolic volume (ESV), fractional area change (FAC) and ejection fraction (EF) (Figure 1(c),(e)).

Figure 1. AroB MO-mediated effects on cardiac functions. (a) Representative images of a lateral view of heart region of 48-hpf embryos (uninjected control (C), InvB MO-injected and AroB MO-injected embryos, and E2 exposed embryos). (a) Atrium; V, Ventricle; L, Length; W, Width. (b) Measurement of heart ventricle at diastolic and systolic phase. Width of ventricle (a); length of ventricle (b); cross-sectional area of ventricle (c). (c) Measurement of EDV, ESV and SV. (d) Measurement of FS, FAC and EF. (e) Measurement of CO. Data are presented as a mean ± SEM. (*) indicates a significant difference compared to control (*p < 0.05). NS, not significant; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; FS, fractional shortening; FAC, fractional area change; EF, ejection fraction; and CO, cardiac output.
Therefore, embryos injected with 5 ng/nL AroB MO were used for further experiments. Injections of InvB MO did not show any significant difference in all parameters measured compared to the uninjected control (Figure 1(b–e)). In addition, there is no change on body length of zebrafish embryos injected with AroB MO or InvB MO compared to control (data not shown), indicating that AroB modulated the changes on ventricular size and cardiac functions.

Because AroB MO inhibits the synthesis of endogenous E2, AroB MO-injected embryos were exposed to E2 to investigate whether E2 able to ameliorate the effects caused by AroB MO. In this experiment, the dose of E2 was applied according to a previous report [3]. Besides, embryos exposed to E2 range from 0.01–1 μM able to induce AroB expression without showing the developmental defects [2,15]. Exposure to E2 did not show any changes on morphology of the ventricle (Figure 1(a)) and in all parameters measured (Figure 2(a–e)). Exposure to 1 μM E2 partially reversed all the parameters caused by AroB MO (Figure 2(b–e)).

4. Discussion

This report demonstrated that heart development and functions were affected by AroB MO-mediated knockdown. Moreover, E2 attenuated the effects caused by AroB MO, suggesting the necessity of E2 produced by AroB in the cardiovascular system. The decreased of ventricular size during diastolic phase, EDV, FS, SV and CO with normal EF in AroB MO-mediated knockdown showed similar features as observed in patients with heart failure with preserved ejection fraction (HFpEF), resulted from left ventricular diastolic dysfunction (LVDD) [16]. Previous study indicates that Aro deficient (ArKO) mice result in a significant decrease in ventricular weight index (VWI), although no changes in total heart weight [17]. Similarly, zebrafish embryos exposed to AI shows smaller ventricular area [4], which is support the possibility that AroB is involved in modulating cardiotropic effect.

Ventricular dysfunction in MO-mediated knockdown could be a result of ventricular tissues remodelling. E2 deficiency is known to stimulate cardiac inflammation and subsequently promote myocardial fibrosis and hypertrophy [16]. The action of E2 through ERα mediates the anti hypertrophic effect induced by angiotensin II [18]. In addition, GPR30 KO mice shows impairment in left ventricular cardiac functions [19], indicating both genomic and non-genomic E2 signalling pathways are involved in the development of ventricular dysfunction. However, histological tissue changes in MO-mediated knockdown need to be verified.

Previously, it is reported that AroA but not AroB is expressed in adult zebrafish heart, and E2 produced in the brain control the heart rate through central serotonin (5-HT) signalling [3]. Both expressions of tryptophan hydroxylase isoforms (TPH1, TPH2), a rate-limiting enzyme for 5-HT production, are lower in embryos exposed to E2 [3], suggesting that both central and peripheral 5-HT are under the control of E2 signalling. Both TPH isoforms are expressed in human [20] and zebrafish heart (data not shown), giving a possibility that MO-mediated knockdown may directly affect TPH expressed

Figure 2. E2 reversed the effects of AroB MO-mediated knockdown on cardiac functions. (a) Measurement of heart ventricle at diastolic and systolic phase. Width of ventricle (a); length of ventricle (b); cross-sectional area of ventricle (c). (b) Measurement of EDV, ESV and SV. (c) Measurement of FS, FAC and EF. (d) Measurement of CO. Data are presented as a mean ± SEM. (*) indicates a significant difference compared to control (p < 0.05).
in cardiac tissues to regulate the 5-HT level and cardiac function. Indeed, brain 5-HT dysfunction plays a critical role in the pathophysiology of HF [21]. Furthermore, disruptions of non-neuronal TPH1 in mice lead to HF without affecting structural defect [22]. Therefore, further experiment needs to be done to understand the role of E2 on 5-HT neuron in zebrafish heart.

5. Conclusion

In conclusion, this study provides evidence that E2 produced by AroB plays a significant role in normal heart development and functions in embryonic zebrafish.

Disclosure statement

No potential conflict of interest was reported by the author.

ORCID

Zulvikar Syambani Ulhaq http://orcid.org/0000-0002-2659-1940

References

[1] Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology. 2001;142:4589–4594.
[2] Kishida M, Callard GV. Distinct cytochrome P450 aromatase isoforms in zebrafish (Danio rerio) brain and ovary are differentially programmed and estrogen regulated during early development. Endocrinology. 2001;142:740–750.
[3] Ulhaq ZS, Kishida M. Brain aromatase modulates serotonergic neuron by regulating serotonin levels in zebrafish embryos and larvae. Front Endocrinol. 2018;9:230.
[4] Allgood OE Jr, Hamad A, Fox J, et al. Estrogen prevents cardiac and vascular failure in the ‘listless’ zebrafish (Danio rerio) developmental model. Gen Comp Endocrinol. 2013;189:33–42.
[5] Jazbutyte V, Stumpner J, Redel A, et al. Aromatase inhibition attenuates desflurane-induced preconditioning against acute myocardial infarction in male mouse heart in vivo. PLoS ONE. 2012;7:e42032.
[6] Babiker FA, De Windt LJ, van Eickels M, et al. Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res. 2002;53:709–719.
[7] Pugach EK, Blenck CL, Dragavon JM, et al. Estrogen receptor profiling and activity in cardiac myocytes. Mol Cell Endocrinol. 2016;431:62–70.
[8] Chandrasekar G, Archer A, Gustafsson JA, et al. Levels of 17β-Estradiol receptors expressed in embryonic and adult zebrafish following In Vivo treatment of natural or synthetic ligands. PLoS One. 2010;5:e9678.
[9] Fang HY, Hung MY, Lin YM, et al. 17β-Estradiol and/or estrogen receptor alpha signaling blocks protein phosphatase 1 mediated ISO induced cardiac hypertrophy. PLoS One. 2018;13:e0196569.
[10] Bell JR, Bernasochi GB, Varma U, et al. Aromatase transgenic upregulation modulates basal cardiac performance and the response to ischemic stress in male mice. Am J Physiol Heart Circ Physiol. 2014;306:H1265–74.
[11] National Research Council (US). Committee for the update of the guide for the care and use of laboratory animals. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press (US); 2011.
[12] Hoage T, Ding Y, Xu X. Quantifying cardiac functions in embryonic and adult zebrafish. Methods Mol Biol. 2012;843:11–20.
[13] Liu TY, Lee PY, Huang CC, et al. A study of the adult zebrafish ventricle function by retrospective Doppler-gated ultrahigh-frame-rate echocardiography. IEEE Trans Ultrason Ferroelect Freq Control. 2013;60:1827–1837.
[14] Kim KH, Antkiewicz DS, Yan L, et al. Lrc10 is required for early heart development and function in zebrafish. Dev Biol. 2007;308:494–506.
[15] Kishida M, McLellan M, Miranda JA, et al. Estrogen and xenoestrogens upregulate the brain aromatase isoform (P450aromB) and perturb markers of early development in zebrafish (Danio rerio). Comp Biochem Physiol B Biochem Mol Biol. 2001;129:261–268.
[16] Li S, Gupte AA. The role of estrogen in cardiac metabolism and diabetic function. Methodist DeBakey Cardiovasc J. 2017;13:4–8.
[17] Bell JR, Mellor KM, Wollermann AC, et al. Aromatase deficiency confers paradoxical postischemic cardioprotection. Endocrinology. 2011;152:4937–4947.
[18] Pedram A, Razandi M, Lubahn D, et al. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology. 2008;149:3361–3369.
[19] Delbeck M, Golz S, Vonk R, et al. Impaired left-ventricular cardiac function in male GPR30-deficient mice. Mol Med Rep. 2011;4:37–40.
[20] Gomez TN, Olivares MA, Olivares AM, et al. Immunohistochemically characterization of serotonergic neurons in male transgenic zebrafish. Dev Biol. 2008;313:229–239.
[21] Delbeck M, Golz S, Vonk R, et al. Impaired left-ventricular cardiac function in male GPR30-deficient mice. Mol Med Rep. 2011;4:37–40.
[22] Gomez TN, Olivares MA, Olivares AM, et al. Immunohistochemically characterization of serotonergic neurons in male transgenic zebrafish. Dev Biol. 2008;313:229–239.